Flying The Web For News.
  • Happy Holidays
    Happy Holidays
  • Career Exam Study
    Career Exam Study
  • 2024 Presidential Election
    2024 Presidential Election
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service

Press Release: Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies

Details
Category: Globe NewsWire News Distribution Service

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim safety and proof-of-concept data to be presented at a scientific meeting in 1H 2025


Posted: 2024-10-23 04:01:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Tags

press | release | interius | biotherapeutics | doses


Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies - Newscast

Blow Us A Whistle